Stoke Therapeutics (STOK) Cash from Operations (2018 - 2026)

Stoke Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 60582000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 145.96% year-over-year to 60582000.0; the TTM figure through Mar 2026 stood at 146824000.0 (down 311.13% YoY), while the FY2025 annual figure was 45585000.0, up 152.49% from the prior year.
• Cash from Operations was 60582000.0 for Q1 2026 at Stoke Therapeutics, down from 30454000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 131827000.0 in Q1 2025 to a low of 60582000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 12634176.47 across 5 years, with a median of 21800000.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations sank 165.73% in 2023, then surged 636.62% in 2025.
• A 5-year view of Cash from Operations shows it stood at 22373000.0 in 2022, then increased by 7.71% to 20649000.0 in 2023, then fell by 12.32% to 23193000.0 in 2024, then sank by 31.31% to 30454000.0 in 2025, then sank by 98.93% to 60582000.0 in 2026.
• The last three Cash from Operations figures came in at 60582000.0 (Q1 2026), 30454000.0 (Q4 2025), and 30366000.0 (Q3 2025), per Business Quant data.